TransMedics Group, Inc. (TMDX)
| Market Cap | 2.07B |
| Revenue (ttm) | 401.09M |
| Net Income (ttm) | 32.64M |
| Shares Out | 33.56M |
| EPS (ttm) | 0.94 |
| PE Ratio | 65.84 |
| Forward PE | 56.11 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,513,302 |
| Open | 60.00 |
| Previous Close | 60.53 |
| Day's Range | 59.72 - 62.46 |
| 52-Week Range | 59.72 - 177.37 |
| Beta | 2.06 |
| Analysts | Buy |
| Price Target | 116.10 (+88.17%) |
| Earnings Date | Oct 28, 2024 |
About TMDX
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung trans... [Read more]
Financial Performance
In 2023, TransMedics Group's revenue was $241.62 million, an increase of 158.53% compared to the previous year's $93.46 million. Losses were -$25.03 million, -30.92% less than in 2022.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for TMDX stock is "Buy." The 12-month stock price forecast is $116.1, which is an increase of 88.17% from the latest price.
News
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANDOVER, Mass. , Dec. 12, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-...
TransMedics: A Look At What Is Behind The Loss Of Sales Momentum In H2 2024
TransMedics shares declined 60% from their August peak after a Q3 revenue miss, and more recently by slightly reduced revenue guidance range, surprising investors accustomed to beat-and-raise guidance...
TMDX INVESTIGATION: Robbins Geller Rudman & Dowd LLP Announces Investigation into TransMedics Group, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm
SAN DIEGO , Dec. 3, 2024 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving TransMedics Group, Inc. (NASD...
Zscaler, TransMedics Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Monday.
TransMedics Appoints Gerardo Hernandez as Chief Financial Officer and Provides Updated 2024 Financial Outlook
ANDOVER, Mass. , Dec. 2, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-s...
TransMedics to Host Investor & Analyst Day on December 10, 2024
ANDOVER, Mass. , Nov. 26, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-...
TransMedics to Participate in the Piper Sandler 36th Annual Healthcare Conference
ANDOVER, Mass. , Nov. 19, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-...
TransMedics: Long-Term Thesis Hasn't Changed At All
TMDX's Q3 revenue miss and margin contraction are short-term issues; long-term growth potential remains strong with management's guidance of 4,000 transplants this year and 10,000 in 3-5 years. High e...
TransMedics: Overreaction To Temporary Headwinds (Rating Upgrade)
TransMedics' Q3 results were weak, with revenue declining sequentially due to US transplant volume headwinds and scheduled aircraft maintenance. While the growth of TransMedics' current business is li...
Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation into TransMedics Group, Inc. (NASDAQ: TMDX)
NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a shareholder and consumer rights litigation firm, is investigating whether TransMedics Group, Inc. (“TransMedics Group” or...
TMDX INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Announces Investigation into TransMedics Group, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm
SAN DIEGO , Nov. 1, 2024 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving TransMedics Group, Inc. (NASDA...
TransMedics: Maintaining A Neutral Stance After A Difficult Q3
TMDX which was outperforming the S&P500 by 6x in August, is now only generating half the returns of the benchmark on a YTD basis. The Q3 event appears to have spooked investors and we dive in to cover...
TransMedics: Every Hero Becomes A Bore At Last
TransMedics Group, Inc. faces significant challenges due to aircraft maintenance issues and rising aviation costs, leading to a 42% stock price drop and a HOLD rating. Revenue shortfall is attributed ...
TransMedics: Mistakes Have Been Made, Here's My Updated Outlook
TransMedics shares fell 25% pre-market after a disappointing Q3 report, missing revenue and EPS estimates, with management failing to manage expectations. Despite the poor quarter, the long-term oppor...
These Analysts Cut Their Forecasts On TransMedics Group Following Weak Results
TransMedics Group, Inc. TMDX posted downbeat quarterly results on Monday.
TransMedics Group Posts Weak Results, Joins Harmonic, Crocs, D.R. Horton And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures falling around 50 points on Tuesday.
INVESTIGATION ALERT (NASDAQ:TMDX): DiCello Levitt LLP Is Investigating Investor Claims Against TransMedics Group, Inc. and Encourages TMDX Investors with Losses to Contact the Firm
SAN DIEGO, Oct. 28, 2024 (GLOBE NEWSWIRE) -- DiCello Levitt LLP announces that it is investigating whether TransMedics Group, Inc. (“TransMedics” or the “Company”) (NASDAQ:TMDX) complied with federal ...
TransMedics Group, Inc. (TMDX) Q3 2024 Earnings Call Transcript
TransMedics Group, Inc. (NASDAQ:TMDX) Q3 2024 Earnings Conference Call October 28, 2024 4:30 PM ET Company Participants Laine Morgan - Gilmartin Group, Investor Relations Waleed Hassanein - President...
TransMedics Reports Third Quarter 2024 Financial Results
ANDOVER, Mass. , Oct. 28, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-...
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q4
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
TransMedics Group: This Could Be One Of The Biggest Moats In A Decade
The company's unique FDA-approved multi-organ platform and proprietary aviation division enhance its competitive edge, reducing costs and improving surgical outcomes. While there are risks, including ...
TransMedics to Report Third Quarter 2024 Financial Results on October 28, 2024
ANDOVER, Mass. , Oct. 15, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-...
FMR LLC's Strategic Reduction in TransMedics Group Inc Shares
On September 30, 2024, FMR LLC (Trades, Portfolio) executed a significant transaction involving the sale of 2,281,896 shares of TransMedics Group Inc (TMDX, Financial), a leader in advanced organ tran...
The Ensign Group Set to Join S&P MidCap 400; Curbline Properties & TransMedics Group to Join S&P SmallCap 600
NEW YORK , Sept. 26, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 and S&P MidCap 400: S&P SmallCap 600 constituent The Ensign Group Inc. (NASD: EN...
TransMedics: Wide Moat Player At A Lower Valuation Than Peers
TransMedics is revolutionizing organ transportation with its FDA-approved Organ Care System, improving organ functionality during transport. Significant investments in logistics, including owning airc...